NCT00042250

Brief Summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 1992

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 1992

Completed
10.2 years until next milestone

First Submitted

Initial submission to the registry

July 24, 2002

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 26, 2002

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2002

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2002

Completed
Last Updated

January 24, 2012

Status Verified

January 1, 2012

Enrollment Period

10.4 years

First QC Date

July 24, 2002

Last Update Submit

January 20, 2012

Conditions

Hematologic Malignancies

Keywords

Cell Cycle InterphaseG0G1G2S Phase

Interventions

Chemotherapy for hematologic malignancyDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Histologic proof of one of: * AML, ALL, or AUL * MDS or CMML * CML * OR undergoing bone marrow transplantation. Participants should be: * off therapy for at least two weeks * At least 18 years old or older * Using adequate contraception if of child-bearing capability.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

M.D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Hematologic Neoplasms

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Michael Andreeff, MD, PhD

    M.D. Anderson Cancer Center

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 24, 2002

First Posted

July 26, 2002

Study Start

May 1, 1992

Primary Completion

October 1, 2002

Study Completion

October 1, 2002

Last Updated

January 24, 2012

Record last verified: 2012-01

Locations

US(1)